The current study elucidates a potential new strategy for the treatment of metastatic TNBC based on the modulation of CREB3L1 and cell-surface GRP78 expression by chemotherapy in addition to GRP78-targeted drugs for the elimination of tumor-initiating clones. Here, CREB3L1 is linked to neoplasm.